HIGHLIGHTS
SUMMARY
As TAVR comes of age, clinical indications for TAVR are gradually expanding, from elderly and comorbid patients affected by calcific AS to younger patients, with bicuspid aortic valve, bioprosthesis degeneration, and/or aortic regurgitation (AR), all conditions that potentially require devices with specific features. Types of TAVR Devices Since the first transcatheter implantation of the aortic Cribier-Edwards valve (Edwards Lifesciences, Irvine, CA, USA) in 2002, several new transcatheter heart valves (THV) were introduced and approved for clinical use. Indeed, for annular dimensions that fall between two valve sizes, the choice is between a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.